Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

News Conference News EACTS 2025

Nearly Half of CABG Patients Have New-Onset AF, but It Often Doesn’t Last

Yael L. Maxwell

October 13, 2025

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

News Daily News

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

October 12, 2022

April 2021 News Roundup

News Opinion CV Team Dispatch

April 2021 News Roundup

April 10, 2021

One in Five CABG Patients Develop New-Onset Atrial Fibrillation: EXCEL

News Daily News

One in Five CABG Patients Develop New-Onset Atrial Fibrillation: EXCEL

Michael O'Riordan

February 12, 2018

TCTMD’s Top 10 Most Popular Stories for October 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

October 29, 2017

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Daily News

New Roles for Anticoagulation Clinics in an Era of Non-Warfarin Options

March 01, 2016

News Industry News

Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation

June 12, 2015

News Daily News

当将胺碘酮联合华法林使用时，卒中、全身栓塞风险高于阿哌沙班

October 10, 2014

News Daily News

Stroke, Systemic Embolism Risk Higher When Amiodarone Combined with Warfarin Rather Than Apixaban

October 10, 2014

News Daily News

El Riesgo de Sufrir ACV y Embolismos Sistémicos es Más Alto cuando Combinamos Amiodarona + Warfarina que Amiodarona +Apixaban

October 10, 2014

Amiodarone, Anticoagulation, and Clinical Events in Patients with A-fib: Insights from ARISTOTLE

Presentation

Amiodarone, Anticoagulation, and Clinical Events in Patients with A-fib: Insights from ARISTOTLE

Presenter: Greg Flaker

October 07, 2014

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.